By Donna Loyle, communications specialist, LIMR
Patients diagnosed with glioblastoma and being treated with brain radiotherapy and temozolomide may qualify to participate in a single-arm study that seeks to determine if the oral drug Altace® (ramipril) can reduce the chance of cognitive decline.
Ramipril currently is FDA approved to treat high blood pressure and to reduce the risk of myocardial infarction, stroke and death from cardiovascular causes. For four months during this study, patients diagnosed with glioblastoma take ramipril during radiotherapy and while being treated with concurrent and adjuvant temozolomide.
At regular intervals, participants complete neurocognitive tests and questionnaires measuring cognitive symptoms, mood, fatigue, sleep disturbance and quality of life.
Albert DeNittis, MD, and Paul Gilman, MD, are principal investigators for study #WF1801, which is approved at Lankenau Medical Center and Paoli Hospital. For more information, visit https://www.mainlinehealth.org/research/clinical-trials/wf1801